Large-scale testing (Phase 3)Study completedNCT02394561
What this trial is testing
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
Who this might be right for
Plaque Type Psorisis
Novartis Pharmaceuticals 434